BPC-157: The Angiogenesis Story, Still Mostly in Rodents

The short version

BPC-157 (Body Protection Compound 157) is a synthetic 15-amino-acid peptide originally derived from a protein found in human gastric juice. In animal studies it has been linked to faster healing of tendons, gastric ulcers, and blood vessels, mostly through a mechanism called angiogenesis — the growth of new blood vessels that supply healing tissue.

BPC-157 is not an FDA-approved medicine. It is sold as a research chemical, for laboratory use, not for human consumption. As of 2025, only three small human pilot studies have looked at it directly, one involving just two adults ^[1][2]. Almost everything else known about BPC-157 — including most of what supports its reputation for helping tendons, ligaments, and gut tissue heal — comes from rats and other animal models, not people.

This page describes what has actually been studied, in which species, and what remains unknown. It does not recommend a dose or a use for any person.

What it is

BPC-157 — also designated Pentadecapeptide BPC 157, PL 14736, or PLD-116 — is a synthetic 15-amino-acid peptide (sequence Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val; molecular formula C62H98N16O22) derived from a partial sequence of a human gastric-juice protein called Body Protection Compound. It is described in the literature as a stable pentadecapeptide, meaning it resists breakdown in the gastrointestinal environment better than most peptides its size — one reason early research focused on gut protection before expanding into tendon, ligament, and vascular-repair models.

The first formal pharmacokinetic characterization, in rats and beagle dogs, found linear pharmacokinetics, a very short elimination half-life (under 30 minutes), and modest intramuscular bioavailability (roughly 14-19% in rats, 45-51% in dogs), with rapid breakdown into small peptide fragments that enter normal amino-acid metabolism ^[3]. No comparable pharmacokinetic study has been done in humans.

How it works

BPC-157's repair effects in animal models are most consistently linked to angiogenesis. The best-characterized pathway is up-regulation and internalization of the VEGFR2 receptor, with downstream VEGFR2-Akt-eNOS (nitric-oxide) signaling: in chick chorioallantoic-membrane and rat hindlimb-ischemia models, this increased vessel density and accelerated blood-flow recovery in ischemic muscle, an effect that was blocked when endocytosis was inhibited ^[4].

Additional reported routes include the FAK-paxillin complex (implicated in cell migration), growth-hormone-receptor sensitization in tendon fibroblasts (one proposed explanation for BPC-157's tendon-repair signal), and modulation of the nitric-oxide system and several neurotransmitter systems, including serotonergic and dopaminergic pathways described in a brain-gut-axis review ^[7]. These mechanisms are drawn almost entirely from cell-culture and rodent studies; no human study has confirmed which, if any, operate the same way in people.

What the research shows

Human safety, at very small scale. A first-in-human pilot gave intravenous BPC-157 up to 20 mg to two healthy adults (a 58-year-old man and a 68-year-old woman). It was well tolerated, with no observed adverse events and no measurable changes in cardiac, hepatic, renal, thyroid, or glucose biomarkers ^[1]. This is a two-person safety pilot, not an efficacy trial, and it is one of only three human studies that exist.

Gastric protection — the foundational finding. In Wistar rats, BPC-157 reduced gastric ulcer area and accelerated healing, with an ulcer-formation inhibition ratio of 45.7-65.6% at higher doses and intramuscular delivery outperforming intragastric delivery ^[5].

Tendon repair. In a fully transected rat Achilles tendon model, BPC-157 accelerated healing across biomechanical, functional, microscopic, and macroscopic measures, and stimulated tendocyte outgrowth in cultured cells — better collagen organization and restored tendon integrity versus untreated controls ^[6].

Angiogenesis mechanism. The VEGFR2-Akt-eNOS pathway work described above remains the best-characterized molecular basis for BPC-157's repair claims across tissue types ^[4].

The honest summary, from a 2025 narrative review: despite broad preclinical support, human data are extremely limited — only three pilot studies — rigorous large-scale trials are lacking, and the review recommends BPC-157 be considered investigational and used with caution given regulatory controversy and non-regulated availability ^[2].

Reported effects, cautions & safety

People in research-use communities report a consistent effect cluster around BPC-157. These are compiled from online forums, wellness-clinic write-ups, and narrative reviews quoting anecdotal recovery reports — anecdotal, not clinical evidence, and never tied to a verified dose.

Reported benefits (anecdotal, not clinical evidence): the most common report is faster-feeling recovery from tendon, ligament, and joint injuries — tennis elbow, rotator-cuff strain, old sprains — often described within one to three weeks. Users also frequently describe less day-to-day joint stiffness and pain, improved digestive or gut symptoms (less bloating, cramping, and urgency), and occasionally a general sense of reduced inflammation, faster skin and wound healing, and better sleep, mood, or stress tolerance. All of these are personal accounts; the published human evidence behind them remains three small pilot studies.

Reported adverse effects (anecdotal, not clinical evidence): injection-site redness, stinging, or a small bump is the most common complaint, usually fading within a day. A minority report nausea or mild stomach upset (more often with oral or sublingual products), fatigue in the first week, headache, dizziness or lightheadedness after injecting, transient flushing or warmth, and — rarely — heart palpitations, which commentators treat as a reason to stop and seek medical evaluation.

Cited cautions from the clinical literature:

• The human evidence is extremely thin. Almost everything known about BPC-157 comes from rodent studies; only a handful of small, uncontrolled human pilot reports exist as of 2025, and large, rigorous controlled trials are lacking ^[1][2].
• Much of the foundational research comes from one group, limiting independent replication ^[2].
• Not an approved drug; unregulated products vary in identity, purity, and content outside formal studies ^[2].
• Strong pro-angiogenic activity raises a theoretical concern in cancer — tumors also depend on new blood-vessel growth, and this is mechanism-based reasoning, not a human finding ^[4].
• Banned in competitive sport — BPC-157 is prohibited at all times by the World Anti-Doping Agency under its non-approved-substances category.
• Mechanism-based, unstudied-in-humans concerns also apply to possible interaction with serotonin-affecting medicines, long-term effects of its growth-signaling activity, and use in pregnancy, breastfeeding, or in children.

Where it fits in recovery & tissue-repair research

BPC-157 is the mechanistic anchor of this desk — the compound whose angiogenic, cytoprotective profile shows up, directly or by extension, in every other member here. GHK-Cu works through a different, matrix-building mechanism entirely; GLOW and Wolverine both fold BPC-157 into multi-peptide combinations on the theory that its vascular and cytoprotective signal complements what the other components do. Reading BPC-157 first, on its own evidence, is the clearest way to then judge what those combinations actually add — or simply assume. See the comparison page for the side-by-side.